Author Archives: admin


Stem Cell Clinic > Articles by: admin

Novel form of cell-free therapy revealed by researchers – Drug Target Review

By Stem Cell Treatment

Researchers have developed cytochalasin B-induced membrane vesicles which they suggest could be a new form of cell-free therapy in regenerative medicine.

Work on extracellular microvesicles (ECMVs) derived from human mesenchymal stem cells (MSCs) has revealed a potential new form of cell-free therapy.

ECMVs are microstructures surrounded by a cytoplasm membrane; they have proven to be a prospective therapeutic tool in regenerative medicine due to their biocompatibility, miniature size, safety and regenerative properties. These can be used to circumvent the limitations of existing cell therapies without losing any effectiveness.

Cell therapies are grafts or implants of living tissue, such as bone marrow transplants, used to replace and regenerate damaged organ tissue. They currently have limited applications, as they work differently dependent on conditions and the environment they are placed into. They can also be rejected by the immune system.

A study at Kazan Federal University, Russia, has investigated cytochalasin B-induced membrane vesicles (CIMVs) which are also derived from MSCs and are very similar to natural ECMVs.

Proteome analysis of human MSCs and CIMVs-MSCs. Venn diagram of identified proteins MSCs and CIMVs-MSCs (A). Distribution of the identified proteins in organelles, percent of unique identified proteins (B) (credit: Kazan Federal University).

The scientists studied and characterised the biological activity of MSC-derived CIMVs. A number of biologically active molecules were found in CIMVs, such as growth factors, cytokines and chemokines; their immunophenotype was also classified.They also found that CIMVs could stimulate angiogenesis in the same way as stem cells.

The team came to the conclusion that human CIMVs-MSCs can be used for cell-free therapy of degenerative diseases. Induction of therapeutic angiogenesis is necessary for the treatment of ischemic tissue damage (eg, ischemic heart disease, hind limb ischemia, diabetic angiopathies and trophic ulcers) and neurodegenerative diseases (eg, multiple sclerosis and Alzheimers disease), as well as therapies for damage of peripheral nerves and spinal cord injury.

The group say they are continuing to research the therapeutic potential for artificial microvesicles for autoimmune diseases.

The study was published in Cells.

Continue reading here:
Novel form of cell-free therapy revealed by researchers - Drug Target Review

Choosing the Best Therapy for Patients with Chronic Lymphocytic Leukemia – Curetoday.com

By Stem Cell Treatment

With many targeted treatment options for patients with CLL to use upfront, the question arises as to which one is best for the individual.

Targeted therapies, such as Imbruvica (ibrutinib), Calquence (acalabrutinib) and Venclexta (venetoclax) plus Gazyva (obinutuzumab), have been approved by the Food and Drug Administration (FDA) and have shown to keep patients in remission or reduce the risk of disease progression or death.

The most recent study is the ELEVATE-TN study, which led to the approval of acalabrutinib, Woyach, an associate professor at The Ohio State University Comprehensive Cancer CenterJames, said in an interview with OncLive, a sister publication of CURE. That study was (Leukeran [chlorambucil])/obinutuzumab versus acalabrutinib alone versus acalabrutinib plus obinutuzumab. Acalabrutinib and acalabrutinib/obinutuzumab had significantly improved (progression free survival [PFS]) with about a 90% two-year PFS rate.

In addition to using these medications alone, researchers are studying their use in combination with other drugs, such as Venclexta with Imbruvica, a type of Brutons tyrosine kinase (BTK) inhibitor. BTK inhibitors work by keeping the cancer cells from growing and have shown great results in CLL.

One study looked at combining venetoclax with the BTK inhibitor (Imbruvica) to see if you can both capitalize on the efficacy of the two agents, and then potentially get patients into such deep remissions that they can come off therapy, she said. At the 2019 ASH Annual Meeting, we had the follow-up of The University of Texas MD Anderson Cancer Center study in both the frontline and relapsed/refractory settings, in which the majority of patients are getting minimal residual disease-negative responses. There are a lot of complete responses with fairly limited follow-up off treatment. Most patients are still in remission.

Side effect profile and patient preference can be used to help guide oncologists on which treatment is best to start with, Woyach explained. We have the discussion for patients who are very high-risk, meaning those with TP53 mutations or 17p deletions, she said. The data with the BTK inhibitors looks a little bit stronger compared with that fixed duration of venetoclax/obinutuzumab. For those patients, I'm still trying to steer them towards the BTK inhibitor; however, it's not wrong to (give) venetoclax/obinutuzumab to those patients either.

Imbruvica has the stronger safety and efficacy data, Woyach added. However, with longer follow-up, Imbruvica has more side effects, such as hypertension; bleeding risk; and atrial fibrillation (AFib), or an irregular heartbeat, which has been seen in 10% to 15% of patients, generally those who are older. In addition, arthralgia, myalgia, diarrhea, bruising and gastrointestinal issues can also been experience by patients treated with Imbruvica.

Although patients have to take Calquence twice a day, the medication has fewer side effects, including less cases of AFib and hypertension. The same bleeding risk as Imbruvica is present, Woyach said. She added that the downside to the Venclexta and Gazyva combination is that they are time consuming.

Overall, these therapies continue to show great promise, but if a patient relapses or becomes resistant to therapy, Woyach explained that reversible BTK inhibitors are in development. A few of those reversible molecules (were presented) at the 2019 ASH Annual Meeting and showed very interesting efficacy; these included ARQ 531 and LOXO-305, she said.

This article was adapted from an article that originally appeared on OncLive, titled Woyach Highlights Progress and Next Steps in CLL Paradigm.

Read the original post:
Choosing the Best Therapy for Patients with Chronic Lymphocytic Leukemia - Curetoday.com

Astellas, Adaptimmune to develop CAR-T & TCR T-cell therapies – BSA bureau

By Stem Cell Treatment

Astellas will pay Adaptimmune an upfront payment, research funding, development and commercial milestones, and royalties on net sales on co-commercialized products

Japan based Astellas Pharma Inc., through its wholly-owned subsidiary Universal Cells, Inc. and Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, have announced that they have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.

Astellas and Adaptimmune will agree on up to three targets and co-develop T-cell therapy candidates directed to those targets. These targets will exclude target specific T-cell products in pre-clinical or clinical trials or those developed for other partners at Adaptimmune. The collaboration will leverage Adaptimmune's target identification and validation capabilities for generating target-specific T-cell Receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently of the HLA profile of the tumor cell. The collaboration will also utilize Astellas Universal Donor Cell and Gene Editing Platform it obtained through the acquisition of Seattle-based Universal Cells.

Adaptimmune has been collaborating with Universal Cells since 2015 on development of gene-edited iPSC cell lines, for which Adaptimmune has rights to develop and commercialize resulting T-cell therapy products using its proprietary process for generating T cells from stem cells without the use of feeder cell lines.

Astellas will fund research up until completion of a Phase 1 trial for each candidate. Upon completion of the Phase 1 trial for each candidate, Astellas and Adaptimmune will elect whether to progress with co-development and co-commercialization of the candidate, or to allow the other Party to pursue the candidate independently through a milestone and royalty bearing licence, with the agreement allowing for either company to opt out. The companies will each have a co-exclusive licence covering the co-development and co-commercialization of the product candidates within the field of T-cell therapy. If a candidate is developed by one company only, the appropriate licences will become exclusive to the continuing party.

Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates independently. Astellas will have sole rights to develop and commercialize these products, subject to necessary licenses and the payment of milestones and royalties.

Under the terms of the agreement, Adaptimmune may receive up to $897.5 million in payments, including:

In addition, Adaptimmune will receive research funding of up to $7.5 million per year.

Finally, Adaptimmune would receive tiered royalties on net sales in the mid-single to mid-teen digits.

Under the terms of the agreement, Astellas may receive up to $552.5 million, including:

In addition, Astellas would receive tiered royalties on net sales in the mid-single to mid-teen digits.

To the extent that Astellas and Adaptimmune co-develop and co-commercialize any T-cell therapy, they will equally share the costs of such co-development and co-commercialization, with the resulting profits from co-commercialization also shared equally. Further details governing co-development and co-commercialization will be articulated in a product-specific commercialization agreement.

The impact of this transaction on Astellas financial results in the fiscal year ending March 31, 2020 will be limited.

Continued here:
Astellas, Adaptimmune to develop CAR-T & TCR T-cell therapies - BSA bureau

Melton parents of seriously ill little girl appeal for help to treat her – Melton Times

By Stem Cell Treatment

The parents of a two-year-old Melton girl, who suffers regular seizures and has brain damage, are desperately trying to raise tens of thousands of pounds to pay for treatment here and abroad to help her live a healthier life.

Anika Wojciechowski has been diagnosed with Wolf-Hirschhorn syndrome and has spent a large part of her short life being treated in hospital.

She has severe epilepsy, endures up to 90 seizures a day and often requires oxygen or CPR to revive her.

Dad, Mariusz, and mum, Katarzyna, are hopeful that treatment elsewhere in Europe can ease their daughters condition depite being told by doctors in the UK that there is little more they can do for her other than prescribing the medication she is on.

They are hopeful that a course of growth hormone therapy and, possibly, stem cell transplantation can help her.

Mariusz told the Melton Times: Anika needs to be watched 24/7 as nobody knows what the next seizure is going to be like.

Her seizures are unpredictable and so one time she will need a bit of oxygen to get over it but the next time she will have a cardiac or respiratory arrest and need CPR done before an ambulance arrives.

He added: Every day, Anika proves how brave she is and she doesnt give up despite everything that has happened to her.

Last year she spent three months in intensive care, being incubated many times and having continuous doses of morphine, ketamine and many other medical agents which kept her in a pharmacological coma to stop her continuous epilepsy attacks.

Many doctors have already given up and see no hope for her but we do continue to fight for her to get the treatment abroad which can help her.

Anika spent the first month of her life in hospital after being born at just 34 weeks and weighing only just over three pounds.

But she developed severe epilepsy and was then diagnosed with the rare Wolf-Hirschhorn syndrome, where the symptoms are a characteristic facial appearance, delayed growth and development, intellectual disability and seizures.

Last year, she was also found to have brain damage and lost her eyesight, all speech abilities and the power in her legs and hands.

In addition, she is very delicate and easily catches a cold and infections, which also result in hospital stays.

Medical professionals did not give her any chance of survival but the couple have sought advice and they say recent initial treatment in europe has perked her up.

Anika already feels and looks better, said Mariusz

She has begun to smile and, even wonderfully, laugh.

Her fragile body is getting stronger and Anika is able to partially control the movement of her head and hands.

What has brought such a great positive effect is only the beginning of the whole treatment, which unfortunately is expensive and requires travelling abroad.

Mariusz and Katarzyna have used their savings and a large proportion of their earnings to fund treatment for their daughter.

They are also grateful for the 4,000 people have pledged on online fundraising pages and collection boxes in local shops.

The couple plan to visit clinics in Poland, Italy and Germany to seek treatment and their main aim is to fund growth hormone therapy for Anika, which is not available on the NHS and which costs around 10,000 just to get started on.

Mariusz added: We are asking people to please help Anika because we know that she can have a normal life and enjoy it like other children but time is running out.

Go to http://www.facebook.com/marian.wojciech.9 to pledge money for Anikas treatment.

See the rest here:
Melton parents of seriously ill little girl appeal for help to treat her - Melton Times

Stem Cell Therapy for Dogs and Cats Is Innovative at Stafford Veterinary Hospital – By MARIA SCANDALE – The SandPaper

By Adult Stem Cells

Stafford Township, NJ Stem cell therapy is an incredible process for healing damaged tissue, so it seems remarkable that it is availablefor petsright here in Manahawkin. Stafford Veterinary Hospital, at 211 North Main St., began offering the advanced treatment in 2019, under the direction of Michael Pride, medical director at the facility.

There, stem cell therapy is most commonly applied to osteoarthritis, but can also be used in dogs suffering from hip dysplasia and ligament and cartilage injuries, as well as mobility ailments and some chronic inflammatory issues such as inflammatory bowel disease and chronic kidney disease, which is common in cats.

Stem cell therapy is actually the only thing that can help to reverse the process of arthritis, Pride said. Everything else is a Band-Aid.

This process can actually help to rebuild cartilage and really reduce inflammation without the need of using aspirin-type medications, Pride said. Its a newer technology that we can use to avoid chronic use of medications, which might actually be detrimental in the long term for the liver or kidneys.

Stem cell therapy treats the source of the problem by offering the ability to replace damaged cells with new ones, instructs the website staffordvet.com.

Stem cells are powerful healing cells in the pets body that can become other types of cells. For example, in the case of arthritis, stem cells can become new cartilage cells and have natural anti-inflammatory properties, thus reducing pain and increasing mobility.

The stem cells are your primary structural cell for all other cells in the body; they can differentiate into almost any other cell, explained Pride. Were processing it down into that primordial stem cell; were activating it, and were injecting it into where it needs to be, and it just starts taking on the characteristics of the cells around it.

Table-top machines from MediVet Biologics are the first Adipose Stem Cell therapy kits for in-clinic use, a major advancement. Stem cell therapy for animals has been commercially available since 2004. MediVet pioneered in-clinic treatment options around 2010.

Pride believes Stafford Veterinary Hospital offers the only such treatment in the immediate area; another is in Egg Harbor Township, Atlantic County.

Were always trying to figure out different ways to help the patient without hurting them, he said while petting a kitten that had been a patient for another type of treatment.

As stem cell therapy is more in the news regarding humans, a pet owners first question might be where the stem cells come from that are used in the process. The answer: from fat tissue of the pet itself, extracted and processed the same day.

As the therapy has been refined in the last decade, it has actually started to become a lot easier, more cost-effective more recently, said Pride, since weve been able to process fat tissue instead of actually getting bone marrow.

Fat tissue actually has a much higher concentration of adult stem cells than bone marrow does, so its less painful for the patient, they heal a lot easier, and we dont have to process it in a different facility.

Everything comes from the animal, and we give it back to the animal. Nothing comes from another animal. We dont have to worry about them rejecting the sample; its their own tissue, and were giving it back to them.

The pet typically goes home the same day after about eight hours. First, X-rays and a consultation with the veterinarian can determine whether the pet is a candidate for the treatment.

A pet owner may not even know that their animal has arthritis.

Cats have a lot of inflammatory issues that they tend to be very good at hiding, said Pride. A lot of people dont realize that they have arthritis. They think, oh, my cats just getting older; hes not jumping as much; hes not as strong; hes just sleeping most of the day, but actually he has arthritis. Its very difficult to diagnose in cats. A lot of times you end up having to do X-rays to find where the arthritic joints happen to be.

An inch-and-a-half incision is the minor surgery that harvests the fat tissue from the belly while the pet is anesthetized. For a cat, about 20 gramsare extracted. For a large dog, about 40 gramsare needed. While the pet is recovering from the incision surgery, the veterinary hospital is processing the sample. When the sample is ready, the pet is sedated because we then have to give them the joint injections. Then we can reverse the sedation, and they go home.

We asked the doctor if the process always works. He gave the example that on average, a dog such as a boxer that was hobbled is now able to walk without seeming like its painful. In an extreme positive case, a dog that had been barely walking might be bouncing all over the place in two months.

It doesnt always work to the extent that we would love it to, but we usually notice that there is a positive effect from it, Pride remarked. Every patient will be different in what they experience.

For the same reason that everyones situation is going to be different, cost of treatment was not given for this story.

It generally takes about 30 to 60 days for relief to show, the veterinarian said, and the animals progress will be monitored.

On average, results last about 18 months to two years before more stem cells might have to be injected. The procedure takes about an hour.

The nice thing is once we collect those stem cells (from the first procedure), we can bank the leftovers they are cryogenically stored at MediVet corporate headquarters in Kentucky and we dont have to go through the initial anesthetic surgery, said Pride.

Stem cell therapy is one of several innovative modalities available at Stafford Veterinary Hospital. Laser therapy, acupuncture and holistic medicine are others. Care for exotic pets is available, as is emergency pet care.

Visit the website staffordvet.com or call 609-597-7571 for more information on general and specialized services, including: vaccinations, microchipping, spayingand neutering, dental care, wellness exams, dermatology, gastrology, oncology, opthalmology, cardiology, soft-tissue surgery, ultrasound, radiography, nutrition, parasite control, boarding, laborand delivery, end-of-life care, and cremation.

Stafford Veterinary Hospital has been in business since 1965, founded by Dr. John Hauge. Today, five highly skilled veterinarians are on staff, and a satellite, Tuckerton Veterinary Clinic, is at 500 North Green St. in Tuckerton.

Pride has been medical director at Stafford Veterinary Hospital since 2008. He attended Rutgers University, then earned his Veterinary of Medicine degree at Oklahoma State University.

The mild-mannered doctor feels a great rewardfrom treating animals that cant speak for themselves when they feel bad.

These guys, theyre always thankful; you can see what they think, he said of treated pets. The turnaround in their attitude, the turnaround in their ability to be more comfortable, you can see it in their faces; you can see it in their actions. You learn to read animals over time.

Its knowing that were helping those who cant help themselves, he added, and you can see it in them; thats the most gratifying.

mariascandale@thesandpaper.net

Go here to read the rest:
Stem Cell Therapy for Dogs and Cats Is Innovative at Stafford Veterinary Hospital - By MARIA SCANDALE - The SandPaper

Why stem cells could be the medical innovation of the century – World Economic Forum

By Stem Cell Clinics

Right now, your bodys stem cells are working hard replacing your skin every two weeks, creating new red and white blood cells and completing thousands of other tasks essential to life. They are your own personalized fountain of youth.

Scientists generally agree that a stem cell should be able to do both of the following:

One theory of ageing suggests that between the ages of 30 and 50, our stem cells reach a turning point and start to decline in number and function. This results in the typical features associated with ageing.

There does not seem to be a single discoverer of stem cells. Accounts date back to the 1800s and even further, but the first successful medical procedure was a bone marrow transfusion in 1939. Advances in immunology led to donor matching, initially via siblings and close relatives. Unrelated donor matching flourished in the 1970s, alongside donor registries.

In the 1980s, scientists identified embryonic stem cells in mice, leading to the 1997 cloning of Dolly the Sheep. This created immense interest for human and medical applications and a backlash in the US as federal R&D funding was essentially halted in 2001.

In 2012, a Nobel Prize was awarded for the earlier discovery of induced pluripotent stem cells (iPS). Essentially, they return potency and self-renewal properties to mature non-stem cells, essentially making them act like stem cells again.

In the decade between 2010 and 2019, the first wave of stem cell start-ups emerged, alongside R&D programmes at many large pharmaceutical companies, leading to innovation and the first human clinical trials for iPS and other related therapies.

According to Q3 2019 data from the Alliance for Regenerative Medicine, there are 959 regenerative medicine companies worldwide sponsoring 1,052 active clinical trials; 525 of these companies are in North America, 233 in Europe and Israel, and 166 in Asia. In aggregate, $7.4 billion has been invested in regenerative medicine companies in 2019; $5.6 billion of which has been dedicated to gene and gene-modified cell therapy, $3.3 billion in cell therapy, and $114 million in tissue engineering.

Overview of the cancer stem cells market

Perhaps most excitingly, curative therapies are hitting the market and the results are astonishing: 60% of Acute Lymphoblastic Leukemia patients taking Novartis Kymirah showed a complete response (no traces of cancer) and were declared in full remission. Meanwhile, 75% of patients with Transfusion-Dependent -Thalassaemia treated with bluebird bios Zynteglo achieved independence from transfusions. Perhaps most astonishingly, 93% of spinal muscular atrophy patients treated with Novartis Zolgensma were alive without permanent ventilation 24 months after treatment. We should expect more medical breakthroughs in the coming years.

New science, new start-ups: several companies in the sector have gone public or been acquired. These exits led to the recycling of talent and capital into new companies. Because the science and commercial systems have also advanced, the companies in the next wave are pursuing bigger challenges, driving innovation, with even greater resources.

Patients are eager: the current market for stem cell therapies is growing at 36% per year, though it will rapidly expand when a breakthrough occurs toward the treatment of a non-communicable disease (such as cancer, diabetes, heart disease) or a lifestyle factor (for example, growing hair in the correct places, expanding cognitive abilities or increasing healthy lifespan).

New R&D models: funding is flowing into the sector from large companies, VC funds, and institutions such as the California Institute for Regenerative Medicine (CIRM) and New York State Stem Cell Science programme (NYSTEM). Some of the leading university R&D platforms include the Center for the Commercialization of Regenerative Medicine in Toronto, the Stanford Institute for Stem Cell Biology and Regenerative Medicine, the Oxford Stem Cell Institute, and most notably, the Harvard Stem Cell Institute (HSCI).

Founded in 2004, HSCI has established a phenomenal track record. It provided the first $200,000 in funding to Derrick Rossis lab, which inspired the largest biotech IPO to date. HSCI scientists were also co-founders or principals in the three most prominent gene-editing companies (CRISPR Tx, Intellia and Editas), the combined $1.55-billion True North/iPierian acquisitions and the recent $950-million acquisition of Semma Tx, Frequency Tx, Fate Tx, Epizyme Inc., and Magenta Tx.

For the casual investor, Evercore ISI is building a Regenerative Medicine Index, which may be the simplest way to build a portfolio. For institutions and those with deeper pockets, regenerative medicine funds are forming, including the Boston-centric Hexagon Regenerative Medicine Fund, which aims to create companies out of the Harvard Stem Cell Institute.

Caveat emptor. Though patients needs are immediate, those seeking treatments should think very carefully about the risks. There are many dubious clinics touting expensive stem cell treatments and some patients have experienced horrifying complications. Dr. Paul Knoepfler of UC-Davis has written a practical and scientifically accurate guide, a strongly recommended read if you or a family member are considering treatment or a clinical trial.

The leading causes of death in 1900 were mostly infectious/communicable diseases. While the prevalence of most causes has diminished, the largest increases include heart disease (+40%) and cancer (+300%). Granted, this is partly due to doubling life expectancy and a lack of death from other causes. However, given time and resources, scientists and physicians may cure these challenging diseases.

Total disease burden by disease or injury

Today, six of the seven leading causes of death are non-communicable diseases (heart disease, stroke, lung diseases, cancer, Alzheimers disease and diabetes). Based on the early promise mentioned above, regenerative medicine may be our best hope to solve the great non-communicable diseases of our time, and perhaps the single most transformative medical innovation in a century.

License and Republishing

World Economic Forum articles may be republished in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Read more:
Why stem cells could be the medical innovation of the century - World Economic Forum

Astellas and Adaptimmune team up in CAR-T development – European Biotechnology

By Induced Pluripotent Stem Cells

Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.

At J.P. Morgan conference, the British company announced that Astellas has agreed to co-develop and co-commercialize stem-cell derived allogeneic CAR-T and TCR T-cell therapies against up to three targets. In contrast to current autologous T cell therapies, allogenic T cell therapies might be manufactured in a central facility reducing production cost significantly compared to autologous cell production and logistics.

Under the agreement, Adaptimmune will identify and validate new targets for generating target-specific T-cell receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently from the HLA profile of the tumour cell. Astellas subsidiary Universal Cells, Inc will provide its Universal Donor Cell and Gene Editing Platform, which makes use of a stem cell-tropic rAAV vector for engineering humanpluripotent stem cells to contain deletions, insertions, or point mutations at any genomic position.

Adaptimmune has been collaborating with Universal Cells since 2015 on development of gene-edited induced pluripotent stem cell (iPSC) lines that generate proprietary T-cell products without the use of feeder layers.

Under the agreement, Astellas will fund research up until completion of a Phase I trial for each candidate with US$7.5m per year. Subsequently, Astellas and Adaptimmune may opt for co-development and co-commercialization of the candidate, or independent development through a milestone and royalty bearing licence. Under the agreement, Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates on its own.

In case of Astellas would develop the candidates on its own, Adaptimmune may receive up to$897.5m in payments. If Adaptimmune would do so, Astellas may receive up to US$552.5m. If the companies opt for co-commercialisation any T-cell therapy, costs and profits will be shared equally.

See more here:
Astellas and Adaptimmune team up in CAR-T development - European Biotechnology

Stem Cell Therapy Market Rising Demand for Digitization in Organizations and Growth till 2027 – Galus Australis

By Induced Pluripotent Stem Cells

The report provides in-depth analysis on the topic and discuss drivers, restraints and opportunities available in the market. The service is designed to help our clients in their decision support system. The analysis also cover the complete spectrum of the research topic to help our clients meeting their business objective.

Stem cell therapy is a technique which uses stem cells for the treatment of various disorders. Stem cell therapy is capable of curing broad spectrum of disorders ranging from simple to life threatening. These stem cells are obtained from different sources, such as, adipose tissue, bone marrow, embryonic stem cell and cord blood among others. Stem cell therapy is enables to treat more than 70 disorders, including degenerative as well as neuromuscular disorders. The ability of a stem cell to renew itself helps in replacing the damaged areas in the human body.

Download a Sample Report Explore further @https://www.theinsightpartners.com/sample/TIPHE100000991

Increase in the number of stem cell banking facilities and rising awareness on the benefits of stem cell for curing various disorders are expected to drive the market during the forecast period. Rise in number of regulations to promote stem cell therapy and increase in number of funds for research in developing countries are expected to offer growth opportunities to the market during the coming years.

Top Dominating Key Players:

1. MEDIPOST2. PHARMICELL Co., Ltd3. Holostem Terapie Avanzate S.r.l.4. Mesoblast Ltd5. U.S. Stem Cell, Inc.6. BIOTIME, INC.7. Lonza8. Caladrius9. Takeda Pharmaceutical Company Limited10. KOLON TISSUEGENE INC.

The stem cell therapy market is segmented based on type as, adult stem cell, embryonic stem cell induced pluripotent stem cell and others. The adult stem cells segment is further segmented as hematopoietic, umbilical cord, neuronal and mesenchymal stem cells. Based on treatment, the market is categorized as allogeneic and autologous. The market is categorized by application as, muscoskeletal, dermatology, cardiology, drug discovery & development and others.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global stem cell therapy market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The stem cell therapy market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting stem cell therapy market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the stem cell therapy market in these regions.

Request for Buy Report @https://www.theinsightpartners.com/buy/TIPHE100000991

Reasons to Buy the Report:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

The Insight partners,

Phone: +1-646-491-9876Email:sales@theinsightpartners.com

Visit link:
Stem Cell Therapy Market Rising Demand for Digitization in Organizations and Growth till 2027 - Galus Australis

Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines – Yahoo Finance

By Induced Pluripotent Stem Cells

Allele Biotechnology and Pharmaceuticals, Inc. (President and CEO: Jiwu Wang, Ph.D., "Allele"), a San Diego-based private company, and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), through its Massachusetts-based subsidiary Astellas Institute for Regenerative Medicine (AIRM), entered into a licensing agreement to expand Astellas access to Alleles induced pluripotent stem cell (iPSC) technologies for various cell therapy programs.

Astellas, one of the largest pharmaceutical companies in Japan and already a leader in the development of cell-based therapeutics, has further dedicated to development of the field through its commitment to state-of-the-art iPS cell generation, modification, and manufacturing. iPSC lines can differentiate into all somatic tissue types, enabling a wide variety of therapeutic applications. The field of iPSC-derived cells has seen dramatic growth in clinical trials recently--the majority of the ~12 clinical trials around the world were initiated within the last 18 months and many more are upcoming.

Allele has been developing its core strength in reprogramming somatic cells into iPSCs with granted patents and the first commercial cGMP system it developed over the past 10 years. Allele also engages in more than a dozen different human tissue derivation activities through its own R&D efforts for internal programs and partnerships. To realize the unparalleled potential of iPSC, Alleles researchers and cGMP team are committed to setting up and validating cell assays for product quality control, genome analysis pipelines, closed-system automation for reprogramming, and machine learning in iPSC-related fields.

Under the terms of the new license agreement, Astellas will pay Allele upfront and milestones, product-based royalties, and potentially manufacture fees.

About AlleleAllele Biotechnology and Pharmaceuticals was founded in 1999. In 2015, the company completed an 18,000 square foot state-of-the-art facility in San Diego for the production of GMP-grade human iPSC lines. The facility also supports the production of tissue-specific cells differentiated from these iPSCs, including pancreatic beta cells, neural progenitor cells, and cardiomyocytes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005668/en/

Contacts

Allele Biotechnology and Pharmaceuticals, Inc.Daniel Catrondcatron@allelebiotech.com +1 858-587-6645

View post:
Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - Yahoo Finance

Researchers have managed to bio-print a functional mini-liver in 90 days – FLWL News

By Induced Pluripotent Stem Cells

Brazilian researchers claim to have bio-printed hepatic organoids. These are miniature versions of livers obtained from human blood cells. However, these mini-organs would be able to perform all the functions of a liver. This innovation gives new hope in terms of organ transplant.

A functional mini-liverIn their publication in the journal Biofabrication of November 27, 2019, researchers from the Human Genome and Stem Cell Institute in Sao Paulo (Brazil) indicated that they obtained a mini-liver through bio-printing. However, the latter would fulfill all the functions hoped for! These include the production of vital proteins, the storage of vitamins and the secretion of bile.

The researchers explained that they combined several bioengineering techniques. Indeed, the culture of pluripotent stem cells and cell reprogramming have been combined with 3D bio-printing. However, there is a difference compared to previous research. In fact, the cells were placed entirely in the bio-ink before being extruded. Previously, it was simply a matter of individual cells.

Relieve waiting for transplantNo less than 90 days were required, from collecting the patients blood to producing the tissue. First, the researchers reprogrammed the patients blood cells into induced pluripotent stem cells. Then, the differentiation of the cells made it possible to change them into liver cells. Finally, their spheroids may have been associated with bio-ink.

You should know that the project directors have bio-printed not one, but three mini-livers. Logically, the stem cells came from three different donors. The objective? Test the method then analyze the functionalities of the organs and the maintenance of cellular contact. As expected, the method worked much better than in the case of previous research incorporating individualized cells. The researchers said the technique could be replicated on a large scale.

Thus, this innovation could open up new hopes in terms of organ transplants. Indeed, the wait for an organ can be very long, which can be problematic. In China, tensions around the field of organ transplants have given rise to questionable research. In 2017, researchers said they wanted to clone pigs to recover their organs. The objective? To successfully transplant humans with these same organs and end the terrible waiting lists.

Lamia spent a couple of years interning at an organization that offered medical consultation before joining the editorial team at FLWL News. An enthusiastic fitness freak in the room, she offers the best amounts of insights and craft-based writing style to keep us up to date about the medicine industry, health and science.

Email:lamia@flwl.orgPhone: +1 512-845-8162

Read this article:
Researchers have managed to bio-print a functional mini-liver in 90 days - FLWL News

→←